Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/117402
Title: | Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma |
Author: | Zhu, Andrew X. Rosmorduc, Olivier Evans, T.R. Jeffry Ross, Paul J. Santoro, Armando Carrilho, Flair José Bruix Tudó, Jordi Qin, Shukui Thuluvath, Paul J. Llovet i Bayer, Josep Maria Leberre, Marie-Aude Jensen, Markus Meinhardt, Gerold Kang, Yoon-Koo |
Keywords: | Càncer de fetge Quimioteràpia Assaigs clínics de medicaments Placebos Liver cancer Chemotherapy Drug testing Placebos (Medicine) |
Issue Date: | 20-Feb-2014 |
Publisher: | American Society of Clinical Oncology |
Abstract: | PURPOSE: To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial. PATIENTS AND METHODS: Patients with advanced HCC and underlying Child-Pugh class A cirrhosis, who were naive to systemic treatment (N = 720), were randomly assigned to sorafenib plus either erlotinib (n = 362) or placebo (n = 358). The primary end point was overall survival (OS). RESULTS: Median OS was similar in the sorafenib plus erlotinib and sorafenib plus placebo groups (9.5 v 8.5 months, respectively; hazard ratio [HR], 0.929; P = .408), as was median time to progression (3.2 v 4.0 months, respectively; HR, 1.135; P = .18). In the sorafenib/erlotinib arm versus the sorafenib/placebo arm, the overall response rate trended higher (6.6% v 3.9%, respectively; P = .102), whereas the disease control rate was significantly lower (43.9% v 52.5%, respectively; P = .021). The median durations of treatment with sorafenib were 86 days in the sorafenib/erlotinib arm and 123 days in the sorafenib/placebo arm. In the sorafenib/erlotinib and sorafenib/placebo arms, the rates of treatment-emergent serious AEs (58.0% v 54.6%, respectively) and drug-related serious AEs (21.0% v 22.8%, respectively) were similar. AEs matched the known safety profiles of both agents, but rates of rash/desquamation, anorexia, and diarrhea were higher in the sorafenib/erlotinib arm, whereas rates of alopecia and hand-foot skin reaction were higher in the sorafenib/placebo arm. Withdrawal rates for AEs during cycles 1 to 3 were higher in the sorafenib/erlotinib arm. CONCLUSION: Adding erlotinib to sorafenib did not improve survival in patients with advanced HCC. |
Note: | Reproducció del document publicat a: https://doi.org/10.1200/JCO.2013.53.7746 |
It is part of: | Journal of Clinical Oncology, 2014, vol. 33, num. 6, p. 559-566 |
URI: | http://hdl.handle.net/2445/117402 |
Related resource: | https://doi.org/10.1200/JCO.2013.53.7746 |
ISSN: | 0732-183X |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
649304.pdf | 165.12 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.